AdipoSeeds is a Keio University School of Medicine spinout founded in July 2016 and based in Shinjuku, Tokyo, developing platelet-like cells derived from adipose tissue (ASCL-PLC) as regenerative medicine products. It runs two business lines: development of ASCL-PLC-based therapeutics, including ADS-01 for intractable skin ulcers and ADS-02 transfusion-grade platelets, and a PRP (platelet-rich plasma) therapy business that includes contract PRP preparation services run jointly with Kohjin Bio. The company aims to become a global pioneer in platelet-based regenerative medicine, addressing platelet shortages and variability in platelet quality.
1
Round
1
Industry
5
Tags
Oct 16, 2026
Latest raise
Funding activity · 1 round
Oct 16, 2026
Seed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
